Goodwin
Kevin Walsh
- Deals
- 6
- Latest
- Jun 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 6 deals
Often works with
- Arman Oruc 5 deals together
- Dan Karelitz 3 deals together
- Malhar Naik 3 deals together
- Gozde Guckaya 3 deals together
- Daniel Karelitz 3 deals together
- Kingsley L. Taft 2 deals together
- Noelle Dubiansky 2 deals together
- Heath Ingram 2 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jun 2026 | Alloy Enterprises | – | Johnson Controls | Acquisition | Legal adviser to Alloy Enterprises (target) | Announced | – | Manufacturing+2 | Johnson Controls acquisition of Alloy Enterprises |
| May 2026 | Anagram Therapeutics | – | – | Stake | Legal adviser to Anagram Therapeutics (target) | Announced | – | Biotech+2 | Stake in Anagram Therapeutics |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Legal adviser to Perfuse Therapeutics (target) | Announced | 300.0 | Biotech+2 | Bayer acquisition of Perfuse Therapeutics |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Legal adviser to LimmaTech Biologics AG (target) | Pending | 780.0 | Biotech | Eli Lilly and Company acquisition of LimmaTech Biologics AG |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Legal adviser to Ouro Medicines (target) | Announced | 1,675.0 | Biotech+1 | Gilead acquisition of Ouro Medicines |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Legal adviser to Synnovation Therapeutics (seller) | Announced | 2,000.0 | Biotech+2 | Novartis acquisition of Pikavation |
Deals where Kevin Walsh is named on the firm's deal team, by the firm or the press.